Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Cancer Vaccines and Peptides

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3343
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Cancer Vaccines and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Cancer Vaccines and Peptides.

    To find out more about Triple Analysis: Lung Cancer, Cancer Vaccines and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Cancer Vaccines and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
A&G Pharmaceutical
Abbott
AC Immune
Acceleron Pharma
Active Biotech
Adaptimmune
Adherex
Advanomics
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affymax
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Allos Therapeutics
Allostera
Allosterix
AlphaVax
Altor BioScience
Ambrilia Biopharma
Amgen
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisoma
Anza Therapeutics
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Ardana
Argos Therapeutics
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
AstraZeneca
Attenuon
AVEO
Avila Therapeutics
Axelar
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Benitec
Betapharma
Biogen Idec
Biokine Therapeutics
BioLineRx
BioNTech
BioNumerik
BioSante
Biostar
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celgene
Cell Therapeutics
Celldex Therapeutics
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chiasma
Chong Kun Dang
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
Clinuvel
CLL Pharma
Compugen
Coronado Biosciences
Cosmo Pharmaceuticals
CreaGene
Critical Outcome Technologies
CSL
Curaxis
CureVac
Curis
Cyclacel
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Dendreon
DeveloGen
Digna Biotech
Dong-A
Dongkook Pharm
ECI
Eisai
Elara Pharmaceuticals
Eli Lilly
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
EntreMed
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Etubics
Exelixis
Formula Pharmaceuticals
Fresenius
Galapagos
Galena Biopharma
Gemin X Biotechnologies
Generex
Genmab
GenOdyssee Pharmaceuticals
GENova Biotherapeutics
Genovax
Genta
Genticel
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlobeImmune
GlycoGenesys
GP Pharm
Gradalis
Gryphon Therapeutics
Hanmi
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
immatics biotechnologies
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innovive
Inovio
Insys Therapeutics
Intezyne Technologies
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Karyon-CTT
Kiadis
Kirax
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
MolMed
Mologen
Momotaro-Gene
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Neurocrine Biosciences
NewSouth Innovations
Nidus Laboratories
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
NovaRx
NPS Pharmaceuticals
Oasmia
OncoGenex Pharmaceuticals
OncoMed
OncoMune
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
PBL Therapeutics
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaForm
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Pro-Pharmaceuticals
Progen Pharmaceuticals
Progenics Pharmaceuticals
Protagonist
Protherics
Q Chip
QLT
Radient Pharmaceuticals
Raptor Pharmaceutical
Receptor BioLogix
Regeneron
Regulon
responsif
RESprotect
Rexahn
Rigel
Samyang
Sanofi
Sanofi-Aventis
Sarepta Therapeutics
Sareum
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Serometrix
ShimodaAtlantic Oncology
Shionogi
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Soligenix
Spectrum Pharmaceuticals
SRI International
SuperGen
Supratek Pharma
Switch Pharma
Symphogen
SynDevRx
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Taxolog
Tekmira Pharmaceuticals
Telik
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
Unigene
United Biomedical
Vaccinex
Valeant
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VaxOnco
Vectura
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
Viragen
Virionics
ViroMed
Wyeth
Xerion
Xigen
Xoma
Yakult Honsha
YM BioSciences
Zelos Therapeutics
Zensun
Zhejiang Beta Pharma
Zivena
Zydus Cadila
A Shortlist of Drugs Included are:
A6
abagovomab
abarelix
ABT-510
ADXS11-001
AE-37
AEZS-108
afamelanotide
afatinib
aflibercept
AGS-003
amrubicin hydrochloride
angiopep+paclitaxel
ANZ-207
ARQ-197
astuprotimut-r
Auto TAG vaccine
AVX-701
belagenpumatucel-L
belotecan hydrochloride
bevacizumab
BIBF-1120
BP-GMAX-CD1
BV-NSCLC-001
canfosfamide hydrochloride
CB-10-01
CBP-501
CDX-1307
celecoxib
cetuximab
CG-201
corticorelin acetate
CreaVax-PC
crizotinib
CV-9103
CV-9201
CVac
dacomitinib
DCVax-prostate
deslorelin
docetaxel
E-75
emepepimut-S
endostatin
EP-100
erlotinib
etoposide (1)
etoposide phosphate
FPI-01
gefitinib
GI-4000
goserelin
GSK-2130579A
GV-1001
GVAX
GVX-3322
GX-301
Her-2/Neu peptides
Hi-8 MEL
histrelin
HS-110
icotinib hydrochloride
ICT-107
imMucin
IMO-2055
iniparib
interferon (gamma1b)
interleukin-12
IPP-204106
irinotecan hydrochloride
ISA-P53-01
JX-594
kahalalide F
lanreotide
lapatinib ditosylate
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
MDX-1379
MGN-1601
motesanib diphosphate
MVA-BN Her-2 vaccine
nadroparin
NAFB001
necitumumab
netupitant
nimotuzumab
oblimersen sodium
octreotide
octreotide, LAR
OncoVAX
Onyvax-105
OTS-102
ozarelix
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
paclitaxel polyglumex
pasireotide
pasireotide LAR
pazopanib hydrochloride
pemetrexed disodium
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
ramucirumab
Reximmune-C
rindopepimut
rintatolimod
romurtide
S-488410
SCIB-1
sipuleucel-T
sorafenib tosylate
sotatercept
Survivac
talactoferrin alfa
tegafur + uracil
TG-4010
thymalfasin
tipapkinogene sovacivec
TM-30339
topotecan
TroVax
TS-1
vapreotide, immediate-release
velimogene aliplasmid
verpasep caltespen
vitespen
VX-001

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Cancer Vaccines and Peptides.
    To find out more about Triple Analysis: Lung Cancer, Cancer Vaccines and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Cancer Vaccines and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Lymphoma and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the mechanism/target/effect of Apoptosis. Learn More


Triple Analysis: Lymphoma, Pancreatic Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Antibodies and Peptides
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two compound strategies of Antibodies and Peptides. Learn More


Triple Analysis: Pancreatic Cancer, Apoptosis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Learn More